Compugen Ltd is a biotechnology company that focuses on the discovery and development of novel drug candidates for immuno-oncology and autoimmune diseases
Utilizing its proprietary algorithmic technology platform, the company identifies new therapeutic targets and generates potential antibody candidates. Compugen is engaged in both internal drug development and collaboration with pharmaceutical partners, aiming to enhance treatment options for patients through innovative therapies that leverage the body's immune system to fight cancer and other conditions.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 200 points on Tuesday. The Dow traded up 0.53% to 37,505.25 while the NASDAQ rose 0.51% to 14,980.71. The S&P 500 also rose, gaining, 0.45% to 4,762.12.
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program. Compugen shares jumped 204.1% to $2.22 on Tuesday.
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.46% to 37,476.21 while the NASDAQ rose 0.41% to 14,966.74. The S&P 500 also rose, gaining, 0.38% to 4,758.55.
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the
U.S. stocks traded higher this morning, with the Dow Jones index gaining around more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.17% to 37,369.84 while the NASDAQ rose 0.25% to 14,941.77. The S&P 500 also rose, gaining, 0.17% to 4,748.81.
A support line is a price level where a stock historically stops declining. It can be a flat line all at one price, or it can be a trend line that gradually moves in one direction. Here is a closer look at how this may benefit you.
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the company’s Silicon Valley Bank.
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
